A new breakthrough energy-based cancer therapy has the ability to kill cancer cells with no side effects in five different cancer cell types: breast, prostate, and the pancreas. This new therapy induces […]
Travera’s new technology can predict how patients will respond to hundreds of different drugs or drug combinations before the patients even take the drugs. Their new measurement tool, the Suspended Microchannel Resonator […]
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is currently an unmet medical need. Soligenix is a biotherapeutic business segment dedicated to […]
NFCR Writer David Perry – September 13, 2018 “The trouble with ultrasound is that it doesn’t detect many ovarian cancers early,” says Robert Bast, M.D., Vice President for Translational Research at MD […]
September 5, 2018 A new cancer drug, larotrectinib, has in a very early clinical trial been shown to have a 93% (14/15) effectiveness rate for pediatric cancers; that is to say, for […]
“For the vast majority of cancer—breast, prostate, lung, colon and others—if it is detected early when it is a little lump in that organ and it has not spread, you will live. […]
NCI Press Release August 20, 2018 In a new study, researchers developed a gene expression predictor that can indicate whether melanoma in a specific patient is likely to respond to treatment with […]
NFCR Press Release NFCR Writer David Perry August 17, 2018 NFCR Breakthroughs The good news is that cocoa is good for you. The seeds of Theobroma cacao are packed with flavonoids, organic […]
